DEPRESSION AND ZUNG SELF-RATING DEPRESSION SCALE IN PARKINSON’S DISEASE
Abstract
Patients affected by Parkinson’s disease (PD) experience many non-motor symptoms, including depression. Depression has a negative impact on everyday activities and quality of life. Still, depression is underrecognized and undertreated overall. Among the instruments used to investigate depression in PD, Zung Self-Rating Depression Scale (ZSRDS) is a widely-used questionnaire for screening depressive symptoms and for measuring progress following treatment. In this article, we review the literature concerning depression associated with PD, paying specific attention to ZSRDS as a tool that investigates depression to guide treatment decisions.
References
1. Rousseaux MWC, Shulman JM, Jankovic J. Progress toward an integrated understanding of Parkinson's disease. F1000Res 2017; 6: 1121.
2. Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. Transl Neurodegener 2017; 6: 28.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Neurodegenerative diseases. In Hyde M. (Ed): Rang and Dale’s Pharmacology, Eighth Edition. UK: Elsevier, 2016, 491-495.
4. Suarez-Cedeno G, Suescun J, Schiess MC. Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease. Parkinsons Dis 2017; 2017: 9358153.
5. Al Shahrani M, Heales S, Hargreaves I, Orford M. Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson's Disease. J Clin Med 2017; 6(11): pii: E100.
6. Fontoura JL, Baptista C, Pedroso FB, Pochapski JA, Miyoshi E, Ferro MM. Depression in Parkinson's Disease: The Contribution from Animal Studies. Parkinsons Dis 2017; 2017: 9124160.
7. Mullins N, Lewis CM. Genetics of Depression: Progress at Last. Curr Psychiatry Rep 2017; 19(8): 43.
8. O’Donnell JM, Shelton RC. Drug Therapy of Depression and Anxiety Disorders. In Brunton LL, Chabner BA, Knollmann BC, (Eds): Goodman&Gillman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. USA: Mc Graw Hill Medical, 2011, 397-416.
9. Havelund JF, Heegaard NHH, Færgeman NJK. Gramsbergen JB, Biomarker Research in Parkinson's Disease Using Metabolite Profiling. Metabolites 2017; 7(3): E42.
10. Teter CJ, Kando JC, Wells BG. Major Depressive Disorder. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. (Ed): Pharmacotherapy: A Pathophysiologic Approach, 9th edition. USA: McGraw Hill Medical, 2014, 1047-1066.
11. Marsh L. Depression and Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep 2013; 13(12): 409.
12. Egan SJ, Laidlaw K, Starkstein S. Cognitive Behavior Therapy for Depression and Anxiety in Parkinson's Disease. J Parkinsons Dis 2015; 5(3): 443-451.
13. Szatmari S, Illigens BM, Siepmann T, Pinter A, Takats A, Bereczki D. Neuropsychiatric symptoms in untreated Parkinson's disease. Neuropsychiatr Dis Treat 2017; 13: 815-826.
14. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkin-son’s disease. Parkinsonism Relat Disord 2002; 8(3): 193-197.
15. Wu P-L, Lee M, Huang T-T. Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review. PLoS ONE 2017; 12(7): e0181515.
16. Santiago JA, Bottero V, Potashkin JA. Biological and Clinical Implications of Comorbidities in Parkinson's Disease. Front Aging Neurosci 2017; 9: 394.
17. Goodarzi Z, Mele B, Guo S, Hanson H, Jette N, Patten S, et al. Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurol 2016; 16(1): 244.
18. Schneiderhan ME, Nelson LA, Munro S. Evaluation of Psychiatric Illness. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. (Ed): Pharmacotherapy: A Pathophysiologic Approach, 8th edition. USA: McGraw Hill Medical, 2011, 1077-1085.
19. Ma L, Demin KA, Kolesnikova TO, Kharsko SL, Zhu X, Yuan X et al. Animal inflammation-based models of depression and their application to drug discovery. Expert Opin Drug Discov 2017; 12(10): 995-1009.
20. Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr 2012; 70(8): 617-20.
21. http://www.who.int/substance_abuse/research_tools/zungdepressionscale/en/
22. Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry 1965; 12: 63-70.
23. Mourady D, Richa S, Karam R, Papazian T, Hajj Moussa F, El Osta N et al., Associations between quality of life, physical activity, worry, depression and insomnia: A cross-sectional designed study in healthy pregnant women. PLoS ONE 2017; 12(5): e0178181.
24. Dunstan DA, Scott N, Todd AK. Screening for anxiety and depression: reassessing the utility of the Zung scales. BMC Psychiatry 2017; 17(1): 329.
25. Stania B, Marinescu I, Glavan D, Stania I, Udristoiu I. Unipolar depression and somatic comorbidities in an outpatient popula-tion. Romanian Journal of Psychopharmacology 2016; 16: 23-31.
26. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22(8): 1077-1092.
27. Miwa H, Miwa T. Fatigue in patients with Parkinson's disease: impact on quality of life. Intern Med 2011; 50(15): 1553-1558.
28. Yasui N, Sekiguchi K, Hamaguchi H, Kanda F. The effect of pramipexole on depressive symptoms in Parkinson's disease. Kobe J Med Sci 2011; 56(5): E214-219.
29. Wang Y, Liu H, Du XD, Zhang Y, Yin G, Zhang BS et al. Association of low serum BDNF with depression in patients with Parkinson's disease. Parkinsonism Relat Disord 2017; 41: 73-78.
30. Chagas MH, Tumas V, Loureiro SR, Hallak JE, Trzesniak C, de Sousa JP, et al. Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease. Parkinsonism Relat Disord 2010; 16(1): 42-45.
31. Sisu R, Popescu A, Turcu-Stiolica A, Bogdan M. Depression assessment in patients diagnosted with Parkinson’s disease for clinical practice. Value in Health 2017; 20(9): A715
32. Mrochen A, Marxreiter F, Kohl Z, Schlachetzki J, Renner B, Schenk T et al. From sweet to sweat: Hedonic olfactory range is impaired in Parkinson's disease. Parkinsonism Relat Disord 2016; 22: 9-14.
33. Suzuki K, Miyamoto M, Miyamoto T, Okuma Y, Hattori N, Kamei S et al. Correlation between depressive symptoms and noc-turnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism. Relat Disord 2009; 15(1): 15-19.
34. Smith MC, Ellgring H, Oertel WH. Sleep disturbances in Parkinson's disease patients and spouses. J Am Geriatr Soc 1997; 45(2): 194-199.
35. Rektorová I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399-406.
36. Yasui N, Sekiguchi K, Hamaguchi H, Kanda F. The effect of pramipexole on depressive symptoms in Parkinson's disease. Kobe J Med Sci 2011; 56(5): E214-219.
37. Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm (Vienna) 1996; 103(6): 699-715.
38. Przuntek H, Welzel D, Blümner E, Danielczyk W, Letzel H, Kaiser HJ et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992; 43(4): 357-363.
39. Chagas MH, Tumas V, Rodrigues GR, Machado-de-Sousa JP, Filho AS, Hallak JE et al. Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. Age Ageing 2013; 42(5): 645-649.
40. Turcu-Stiolica A, Taerel AE, Turcu-Stiolica R. Identifying and measuring compliance and adherence in antidepressants taking. Procedia Economics and Finance 2014; 15: 836-839.
2. Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. Transl Neurodegener 2017; 6: 28.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Neurodegenerative diseases. In Hyde M. (Ed): Rang and Dale’s Pharmacology, Eighth Edition. UK: Elsevier, 2016, 491-495.
4. Suarez-Cedeno G, Suescun J, Schiess MC. Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease. Parkinsons Dis 2017; 2017: 9358153.
5. Al Shahrani M, Heales S, Hargreaves I, Orford M. Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson's Disease. J Clin Med 2017; 6(11): pii: E100.
6. Fontoura JL, Baptista C, Pedroso FB, Pochapski JA, Miyoshi E, Ferro MM. Depression in Parkinson's Disease: The Contribution from Animal Studies. Parkinsons Dis 2017; 2017: 9124160.
7. Mullins N, Lewis CM. Genetics of Depression: Progress at Last. Curr Psychiatry Rep 2017; 19(8): 43.
8. O’Donnell JM, Shelton RC. Drug Therapy of Depression and Anxiety Disorders. In Brunton LL, Chabner BA, Knollmann BC, (Eds): Goodman&Gillman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. USA: Mc Graw Hill Medical, 2011, 397-416.
9. Havelund JF, Heegaard NHH, Færgeman NJK. Gramsbergen JB, Biomarker Research in Parkinson's Disease Using Metabolite Profiling. Metabolites 2017; 7(3): E42.
10. Teter CJ, Kando JC, Wells BG. Major Depressive Disorder. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. (Ed): Pharmacotherapy: A Pathophysiologic Approach, 9th edition. USA: McGraw Hill Medical, 2014, 1047-1066.
11. Marsh L. Depression and Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep 2013; 13(12): 409.
12. Egan SJ, Laidlaw K, Starkstein S. Cognitive Behavior Therapy for Depression and Anxiety in Parkinson's Disease. J Parkinsons Dis 2015; 5(3): 443-451.
13. Szatmari S, Illigens BM, Siepmann T, Pinter A, Takats A, Bereczki D. Neuropsychiatric symptoms in untreated Parkinson's disease. Neuropsychiatr Dis Treat 2017; 13: 815-826.
14. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkin-son’s disease. Parkinsonism Relat Disord 2002; 8(3): 193-197.
15. Wu P-L, Lee M, Huang T-T. Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review. PLoS ONE 2017; 12(7): e0181515.
16. Santiago JA, Bottero V, Potashkin JA. Biological and Clinical Implications of Comorbidities in Parkinson's Disease. Front Aging Neurosci 2017; 9: 394.
17. Goodarzi Z, Mele B, Guo S, Hanson H, Jette N, Patten S, et al. Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurol 2016; 16(1): 244.
18. Schneiderhan ME, Nelson LA, Munro S. Evaluation of Psychiatric Illness. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. (Ed): Pharmacotherapy: A Pathophysiologic Approach, 8th edition. USA: McGraw Hill Medical, 2011, 1077-1085.
19. Ma L, Demin KA, Kolesnikova TO, Kharsko SL, Zhu X, Yuan X et al. Animal inflammation-based models of depression and their application to drug discovery. Expert Opin Drug Discov 2017; 12(10): 995-1009.
20. Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr 2012; 70(8): 617-20.
21. http://www.who.int/substance_abuse/research_tools/zungdepressionscale/en/
22. Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry 1965; 12: 63-70.
23. Mourady D, Richa S, Karam R, Papazian T, Hajj Moussa F, El Osta N et al., Associations between quality of life, physical activity, worry, depression and insomnia: A cross-sectional designed study in healthy pregnant women. PLoS ONE 2017; 12(5): e0178181.
24. Dunstan DA, Scott N, Todd AK. Screening for anxiety and depression: reassessing the utility of the Zung scales. BMC Psychiatry 2017; 17(1): 329.
25. Stania B, Marinescu I, Glavan D, Stania I, Udristoiu I. Unipolar depression and somatic comorbidities in an outpatient popula-tion. Romanian Journal of Psychopharmacology 2016; 16: 23-31.
26. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22(8): 1077-1092.
27. Miwa H, Miwa T. Fatigue in patients with Parkinson's disease: impact on quality of life. Intern Med 2011; 50(15): 1553-1558.
28. Yasui N, Sekiguchi K, Hamaguchi H, Kanda F. The effect of pramipexole on depressive symptoms in Parkinson's disease. Kobe J Med Sci 2011; 56(5): E214-219.
29. Wang Y, Liu H, Du XD, Zhang Y, Yin G, Zhang BS et al. Association of low serum BDNF with depression in patients with Parkinson's disease. Parkinsonism Relat Disord 2017; 41: 73-78.
30. Chagas MH, Tumas V, Loureiro SR, Hallak JE, Trzesniak C, de Sousa JP, et al. Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease. Parkinsonism Relat Disord 2010; 16(1): 42-45.
31. Sisu R, Popescu A, Turcu-Stiolica A, Bogdan M. Depression assessment in patients diagnosted with Parkinson’s disease for clinical practice. Value in Health 2017; 20(9): A715
32. Mrochen A, Marxreiter F, Kohl Z, Schlachetzki J, Renner B, Schenk T et al. From sweet to sweat: Hedonic olfactory range is impaired in Parkinson's disease. Parkinsonism Relat Disord 2016; 22: 9-14.
33. Suzuki K, Miyamoto M, Miyamoto T, Okuma Y, Hattori N, Kamei S et al. Correlation between depressive symptoms and noc-turnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism. Relat Disord 2009; 15(1): 15-19.
34. Smith MC, Ellgring H, Oertel WH. Sleep disturbances in Parkinson's disease patients and spouses. J Am Geriatr Soc 1997; 45(2): 194-199.
35. Rektorová I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399-406.
36. Yasui N, Sekiguchi K, Hamaguchi H, Kanda F. The effect of pramipexole on depressive symptoms in Parkinson's disease. Kobe J Med Sci 2011; 56(5): E214-219.
37. Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm (Vienna) 1996; 103(6): 699-715.
38. Przuntek H, Welzel D, Blümner E, Danielczyk W, Letzel H, Kaiser HJ et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992; 43(4): 357-363.
39. Chagas MH, Tumas V, Rodrigues GR, Machado-de-Sousa JP, Filho AS, Hallak JE et al. Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. Age Ageing 2013; 42(5): 645-649.
40. Turcu-Stiolica A, Taerel AE, Turcu-Stiolica R. Identifying and measuring compliance and adherence in antidepressants taking. Procedia Economics and Finance 2014; 15: 836-839.
Published
2018-06-29
Section
INTERNAL MEDICINE - PEDIATRICS
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
